Deloitte: Artificial intelligence technology investments prove top priority for biopharma leaders

Biopharma executives that pursue leapfrog digital innovation will be those best positioned in 2022 to gain an edge over the competition, according to the consultants behind that publication. To better understand the biopharma industry's experience with digital innovation now and in the year ahead, the Deloitte team surveyed 150 biopharma leaders and found that digital technologies such as the cloud (49%), AI (38%), data lakes (33%), and wearables (33%) have been adopted in day-to-day operations. Other technologies such as quantum computing and digital twins are still nascent. Some 82% of respondents agreed that digitalization of operations will continue even after the pandemic ends. Digital innovation is a burning strategic priority for biopharma leaders, found the Deloitte publication.